 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jan 18, 2017 |
| Title |
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple negative breast cancer |
| Organism |
Homo sapiens |
| Experiment type |
Non-coding RNA profiling by high throughput sequencing
|
| Summary |
Little is understood about the early molecular drivers of triple-negative breast cancer (TNBC), making the identification of women at risk and development of targeted therapy for prevention significant challenges. By sequencing a TNBC cell line-based breast cancer progression model we have found that miRNA-29c is progressively lost during TNBC tumorigenesis. In support of the tumor suppressive role of miRNA 29c, we found that low levels predict poor overall patient survival and, conversely, that ectopic expression of miRNA-29c in preneoplastic cell models inhibits growth. miRNA-29c exerts its growth inhibitory effects through direct binding and regulation of TGFB-induced factor homeobox 2 (TGIF2), CAMP-responsive element binding protein 5 (CREB5), and V-Akt murine thymoma viral oncogene homolog 3 (AKT3). miRNA-29c regulation of these gene targets seems to be functionally relevant, as TGIF2, CREB5, and AKT3 were able to rescue the inhibition of cell proliferation and colony formation caused by ectopic expression of miRNA-29c in preneoplastic cells. AKT3 is an oncogene of known relevance in breast cancer, and as a proof of principle we found that inhibition of phosphoinositide 3-kinase (PI3K) activity, a protein upstream of AKT3, suppressed proliferation in TNBC preneoplastic cells. We explored additional opportunities for prevention of TNBC by studying the regulation of miRNA-29c and identified DNA methylation to have a role in the inhibition of miRNA-29c during TNBC tumorigenesis. Consistent with these observations, we found 5 aza-cytadine to relieve the suppression of miRNA-29c. Together, these results demonstrate that miRNA-29c loss plays a key role in the early development of TNBC.
|
| |
|
| Overall design |
To identify small RNA changes that underlie during TNBC progression.
|
| |
|
| Contributor(s) |
Bedrosian I, Bhardwaj A, Coarfa C, Gunaratne PH, Rajapakshe K, Singh H, Tachibana K, Ganesan N, Pan Y |
| Citation(s) |
28160548, 32204397 |
| |
| Submission date |
Jan 17, 2017 |
| Last update date |
Apr 20, 2020 |
| Contact name |
Isabelle Bedrosian |
| E-mail(s) |
[email protected]
|
| Phone |
713-563-5045
|
| Organization name |
UT MD Anderson Cancer Center
|
| Department |
Breast Surgical Oncology
|
| Lab |
PI: Dr. Isabelle Bedrosian
|
| Street address |
1515 Holcombe Street
|
| City |
Houston |
| State/province |
TX |
| ZIP/Postal code |
77033 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL9115 |
Illumina Genome Analyzer II (Homo sapiens) |
|
| Samples (18)
|
|
| Relations |
| BioProject |
PRJNA362231 |
| SRA |
SRP096915 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE93740_bedrosian-mirna.exact4.txt.gz |
56.2 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...